Bin zhou and Liu

Dr. Bin zhou and Liu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Kidney International
Verified
Journal Article
Open access
JLJing Leng
Jing Leng
WZWen Zhao
Wen Zhao
JGJinwei Guo
Jinwei Guo
GYGang Yu
Gang Yu
GZGuanghui Zhu
Guanghui Zhu
BLBin zhou and Liu
Bin zhou and Liu
Necroinflammation plays an important role in disease settings such as acute kidney injury (AKI). We and others have elucidated that prostaglandins, which are critically involved in inflammation, may activate E-prostanoid 3 receptor (EP3) at low concentrations. However, how EP3 blockade interacts with regulated cell death and affects AKI remains unknown. In this study, AKI was induced by ischemia-reperfusion (30 minutes/24 hours) in Ep3 knockout (Ep3-/-), bone marrow chimeric, myeloid conditional EP3 knockout and corresponding control mice. The production of prostaglandins E2 and I2 was markedly increased after ischemia-reperfusion, and either abrogation or antagonism of EP3 ameliorated the injury. EP3 deficiency curbed inflammatory cytokine release, neutrophil infiltration and serum high-mobility group box 1 levels, but additional TLR4 inhibition with TAK-242 did not offer further protection against the injury and inflammation. The protection of Ep3-/- was predominantly mediated by suppressing Mixed Lineage Kinase domain-Like-dependent necroptosis, resulting from the inhibition of cytokine generation and the switching of cell death modality from necroptosis to apoptosis through caspase-8 up-regulation, in part due to the restraint of IL-6/JAK2/STAT3 signaling. EP3 deficiency failed to further alleviate the injury when necroptosis was inhibited. Ep3-/- in bone marrow-derived cells, particularly that in myeloid cells, protected kidneys to the same extent as that of global EP3 deletion. Thus, our results demonstrate that EP3 deficiency especially that on myeloid cells, ameliorates ischemic AKI via curbing inflammation and breaking the auto-amplification loop of necroinflammation. Hence, EP3 may be a promising target for the prevention and/or treatment of AKI.

5 November 2019 in Cardiovascular Research
Verified
Journal Article
Open access
NKNicholas S Kirkby
Nicholas S Kirkby
JRJoan Raouf
Joan Raouf
BABlerina Ahmetaj-Shala
Blerina Ahmetaj-Shala
BLBin zhou and Liu
Bin zhou and Liu
SMSarah I Mazi
Sarah I Mazi
JMJane A Mitchell
Jane A Mitchell
Aims: Cardiovascular side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs), which all inhibit cyclooxygenase (COX)-2, have prevented development of new drugs that target prostaglandins to treat inflammation and cancer. Microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors have efficacy in the NSAID arena but their cardiovascular safety is not known. Our previous work identified asymmetric dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase, as a potential biomarker of cardiovascular toxicity associated with blockade of COX-2. Here, we have used pharmacological tools and genetically modified mice to delineate mPGES-1 and COX-2 in the regulation of ADMA. Methods and results: Inhibition of COX-2 but not mPGES-1 deletion resulted in increased plasma ADMA levels. mPGES-1 deletion but not COX-2 inhibition resulted in increased plasma prostacyclin levels. These differences were explained by distinct compartmentalization of COX-2 and mPGES-1 in the kidney. Data from prostanoid synthase/receptor knockout mice showed that the COX-2/ADMA axis is controlled by prostacyclin receptors (IP and PPARβ/δ) and the inhibitory PGE2 receptor EP4, but not other PGE2 receptors. Conclusion: These data demonstrate that inhibition of mPGES-1 spares the renal COX-2/ADMA pathway and define mechanistically how COX-2 regulates ADMA.

30 August 2024 in Circulation Research
Verified
Journal Article
Closed access
JGJiahui Ge
Jiahui Ge
YZYingbi Zhou
Yingbi Zhou
HLHui Li
Hui Li
RZRuhui Zeng
Ruhui Zeng
KXKaiqi Xie
Kaiqi Xie
BLBin zhou and Liu
Bin zhou and Liu
BACKGROUND: Prostaglandin I 2 synthesized by endothelial COX (cyclooxygenase) evokes potent vasodilation in some blood vessels but is paradoxically responsible for endothelium-dependent constriction (EDC) in others. Prostaglandin I 2 production and EDC may be enhanced in diseases such as hypertension. However, how PGIS (prostaglandin I 2 synthase) deficiency affects EDC and how this is implicated in the consequent cardiovascular pathologies remain largely unknown. METHODS: Experiments were performed with wild-type, Pgis knockout ( Pgis − / − ) and Pgis /thromboxane-prostanoid receptor gene ( Tp ) double knockout ( Pgis − / − Tp − / − ) mice and Pgis − / − mice transplanted with unfractionated wild-type or Cox-1 − / − bone marrow cells, as well as human umbilical arteries. COX-derived prostanoids were measured by high-performance liquid chromatography-mass spectrometry. Vasomotor responses of distinct types of arteries were assessed by isometric force measurement. Parameters of hypertension, vascular remodeling, and cardiac hypertrophy in mice at different ages were monitored. RESULTS: PGF 2α , PGE 2 , and a trace amount of PGD 2 , but not thromboxane A 2 (TxA 2 ), were produced in response to acetylcholine in Pgis − / − or PGIS-inhibited arteries. PGIS deficiency resulted in exacerbation or occurrence of EDC ex vivo and in vivo. Endothelium-dependent hyperpolarization was unchanged, but phosphorylation levels of eNOS (endothelial nitric oxide synthase) at Ser1177 and Thr495 were altered and NO production and the NO-dependent relaxation evoked by acetylcholine were remarkably reduced in Pgis − / − aortas. Pgis − / − mice developed high blood pressure and vascular remodeling at 16 to 17 weeks and subsequently cardiac hypertrophy at 24 to 26 weeks. Meanwhile, blood pressure and cardiac parameters remained normal at 8 to 10 weeks. Additional ablation of TP (TxA 2 receptor) not only restrained EDC and the downregulation of NO signaling in Pgis − / − mice but also ameliorated the cardiovascular abnormalities. Stimulation of Pgis − / − vessels with acetylcholine in the presence of platelets led to increased TxA 2 generation. COX-1 disruption in bone marrow–derived cells failed to affect the development of high blood pressure and vascular remodeling in Pgis − / − mice though it largely suppressed the increase of plasma TxB 2 (TxA 2 metabolite) level. CONCLUSIONS: Our study demonstrates that the non-TxA 2 prostanoids/TP axis plays an essential role in mediating the augmentation of EDC and cardiovascular disorders when PGIS is deficient, suggesting TP as a promising therapeutic target in diseases associated with PGIS insufficiency.

1 January 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
MVMaria Vinokurova
Maria Vinokurova
MLMaria Elisa Lopes-Pires
Maria Elisa Lopes-Pires
NCNeringa Cypaite
Neringa Cypaite
FSFisnik Shala
Fisnik Shala
PAPaul C. Armstrong
Paul C. Armstrong
NKNicholas S. Kirkby
Nicholas S. Kirkby
BACKGROUND: Prostacyclin is a fundamental signaling pathway traditionally associated with the cardiovascular system and protection against thrombosis but which also has regulatory functions in fibrosis, proliferation, and immunity. Prevailing dogma states that prostacyclin is principally derived from vascular endothelium, although it is known that other cells can also synthesize it. However, the role of nonendothelial sources in prostacyclin production has not been systematically evaluated resulting in an underappreciation of their importance relative to better characterized endothelial sources. METHODS: To address this, we have used novel endothelial cell–specific and fibroblast-specific COX (cyclo-oxygenase) and prostacyclin synthase knockout mice and cells freshly isolated from mouse and human lung tissue. We have assessed prostacyclin release by immunoassay and thrombosis in vivo using an FeCl 3 -induced carotid artery injury model. RESULTS: We found that in arteries, endothelial cells are the main source of prostacyclin but that in the lung, and other tissues, prostacyclin production occurs largely independently of endothelial and vascular smooth muscle cells. Instead, in mouse and human lung, prostacyclin production was strongly associated with fibroblasts. By comparison, microvascular endothelial cells from the lung showed weak prostacyclin synthetic capacity compared with those isolated from large arteries. Prostacyclin derived from fibroblasts and other nonendothelial sources was seen to contribute to antithrombotic protection. CONCLUSIONS: These observations define a new paradigm in prostacyclin biology in which fibroblast/nonendothelial-derived prostacyclin works in parallel with endothelium-derived prostanoids to control thrombotic risk and potentially a broad range of other biology. Although generation of prostacyclin by fibroblasts has been shown previously, the scale and systemic activity was unappreciated. As such, this represents a basic change in our understanding and may provide new insight into how diseases of the lung result in cardiovascular risk.

3 August 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TGTingting Guo
Tingting Guo
BLBin zhou and Liu
Bin zhou and Liu
RZRuhui Zeng
Ruhui Zeng
RLRui Lin
Rui Lin
JGJinwei Guo
Jinwei Guo
YZYingbi Zhou
Yingbi Zhou

7 February 2026 in Biochemical Pharmacology
Verified
Journal Article
Closed access
XCXijian Chen
Xijian Chen
JGJiahui Ge
Jiahui Ge
GYGang Yu
Gang Yu
YFYu Fan
Yu Fan
JYJianye Yang
Jianye Yang
YZYingbi Zhou
Yingbi Zhou